HCPLive’s Post

The ACP recommends prescribing an SGLT-2 inhibitor or GLP-1 agonist as an adjunct to metformin and lifestyle modifications to improve glycemic control among adults with type 2 diabetes. Specifically, the ACP recommends SGLT-2 inhibitors to reduce the risks for all-cause mortality, MACE, progression of CKD, and hospitalization due to CHF. To reduce the risk for all-cause mortality, MACE, and stroke, GLP-1 agonists are recommended.

Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes

Remission of type 2 diabetes?? You heard me. Or should I say, you read that correctly!! Long-term testosterone therapy in men with T2DM and hypogonadism improves glycaemic control and insulin resistance. Remission of diabetes occurred in one-third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.

📣 Exciting News Alert! 📣 The American College of Physicians (ACP) just released updated guidelines for managing type 2 diabetes, emphasizing the importance of incorporating SGLT-2 inhibitors and GLP-1 agonists alongside metformin and lifestyle interventions. 🩺💊 Check out the guidelines here: https://lnkd.in/dugvJJdU Key Takeaways: 1️⃣ GLP-1 agonists and SGLT-2 inhibitors are effective for controlling blood sugar levels. 2️⃣ High treatment costs are acknowledged, with strategies suggested to overcome this barrier. 3️⃣ DPP-4 inhibitors aren't recommended due to insufficient evidence. In case of any queries Feel free to reach out! 📩 #DiabetesCare #ACPGuidelines 🌟

For adults with type 2 diabetes and inadequate glycemic control, the authors recommend the addition of an SGLT-2 inhibitor or GLP-1 agonist to metformin and lifestyle modifications (strong recommendation). An SGLT-2 inhibitor can reduce the risk for all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and hospitalization due to congestive heart failure. Use of a GLP-1 agonist can reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke.

Tirzepatide Triumphs: First Trial Shows Major Wins for Heart Failure in Obese Patients 02 Aug, 2024 • In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity. Tirzepatide was approved by the FDA for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and for adults with obesity (a BMI of 30 kg/m2 or greater) or those who are overweight (a BMI of 27 kg/m2 or greater) who also have a weight-related comorbid condition on November 8, 2023. In the SUMMIT Phase III trial, injection with tirzepatide (5 mg, 10 mg or 15 mg) was tested as a possible treatment for heart failure with preserved ejection fraction in obese patients. • Tirzepatide demonstrated statistically significant improvements in both primary endpoints with a reduction in the risk of heart failure outcomes as welll as improvements in heart failure symptoms and physical limitations. When assessing body weight changes, the efficacy estimated indicated patients receiving tirzepatide experienced a mean reduction in body weight of 15.7% vs 2.2% for placebo. Source: Press Release | Read full story https://lnkd.in/dFx4YbFP

Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes, #NEJM In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned patients with type 1 diabetes diagnosed during the previous 100 days to receive baricitinib (4 mg once per day) or matched placebo orally for 48 weeks. The primary outcome was the mean C-peptide level, determined from the area under the concentration–time curve, during a 2-hour mixed-meal tolerance test at week 48. Secondary outcomes included the change from baseline in the glycated hemoglobin level, the daily insulin dose, and measures of glycemic control assessed with the use of continuous glucose monitoring. A total of 91 patients received baricitinib (60 patients) or placebo (31 patients). The median of the mixed-meal–stimulated mean C-peptide level at week 48 was 0.65 nmol per liter per minute (interquartile range, 0.31 to 0.82) in the baricitinib group and 0.43 nmol per liter per minute (interquartile range, 0.13 to 0.63) in the placebo group (P=0.001). The mean daily insulin dose at 48 weeks was 0.41 U per kilogram of body weight per day (95% confidence interval [CI], 0.35 to 0.48) in the baricitinib group and 0.52 U per kilogram per day (95% CI, 0.44 to 0.60) in the placebo group. The levels of glycated hemoglobin were similar in the two trial groups. However, the mean coefficient of variation of the glucose level at 48 weeks, as measured by continuous glucose monitoring, was 29.6% (95% CI, 27.8 to 31.3) in the baricitinib group and 33.8% (95% CI, 31.5 to 36.2) in the placebo group. The frequency and severity of adverse events were similar in the two trial groups, and no serious adverse events were attributed to baricitinib or placebo. https://lnkd.in/e78ANuDi CONCLUSIONS In patients with type 1 diabetes of recent onset, daily treatment with baricitinib over 48 weeks appeared to preserve β-cell function as estimated by the mixed-meal–stimulated mean C-peptide level. (Funded by JDRF International and others; BANDIT Australian New Zealand Clinical Trials Registry number, ACTRN12620000239965 https://lnkd.in/eFnCAtiA

Exciting news for the autoimmune Type 1 Diabetes (T1D) community! Hot on the heels of the 84th Scientific Sessions of the American Diabetes Association, the Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes has been published in Diabetes Care and Diabetologia. This major effort has been led by Breakthrough T1D (formerly known as JDRF), in partnership with over 70 leading clinicians and researchers in the autoimmune T1D space, and with the endorsement of major clinical organizations, including the American Diabetes Association, the European Association for the Study of Diabetes, the International Society for Pediatric and Adolescent Diabetes, and the Endocrine Society, among others. I believe this guidance will provide vital clinical value, as it provides an answer to one of the key questions that I keep hearing from my peers and colleagues: how can we best monitor the progression of autoimmune T1D in someone who has been diagnosed with presymptomatic stages of this condition? Several studies have shown benefits resulting from the early detection of autoimmune T1D, such as: 1. The possibility to reduce the chance of T1D-associated complications such as life-threatening diabetic ketoacidosis 2. Allowing patients and their families more time to prepare for managing this chronic, life-changing disease, to learn and better understand the treatment options 3. Giving people the opportunity to enroll in clinical trials, investigating potential therapies targeting presymptomatic autoimmune T1D. 4. Helping to avoid a misdiagnosis, given some of the symptoms of Stage 3 autoimmune T1D can be confused with other health conditions N/A  On behalf of Sanofi, I want to thank all collaborating parties that made this clinical consensus a reality and to reinforce our commitment to support the adoption and implementation of these guidelines around the world. For those interested in learning more about the different stages of T1D (presymptomatic: Stage 1 & Stage 2; symptomatic/clinical T1D: Stage 3) and most importantly how to care for people living with these presymptomatic stages as the disease progresses, I encourage you to read the publication. At Sanofi, we are looking forward to continuing to collaborate with relevant stakeholders as we keep chasing the miracles of science to improve the lives of those living with autoimmune Type 1 diabetes.

https://lnkd.in/eV2S2PpU Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. #diabetesjlcolina #tirzeptaide #semaglutide